Opiant Pharmaceuticals Inc (NASDAQ:OPNT) insider Phil Skolnick sold 1,821 shares of Opiant Pharmaceuticals stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $18.01, for a total value of $32,796.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Phil Skolnick also recently made the following trade(s):
- On Thursday, October 4th, Phil Skolnick sold 4,778 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $18.32, for a total value of $87,532.96.
NASDAQ:OPNT opened at $16.34 on Wednesday. The stock has a market capitalization of $52.58 million, a P/E ratio of 5.56 and a beta of 0.34. Opiant Pharmaceuticals Inc has a 52-week low of $12.75 and a 52-week high of $36.77.
A number of research firms recently issued reports on OPNT. Cantor Fitzgerald set a $42.00 target price on Opiant Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 4th. ValuEngine downgraded Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 28th.
An institutional investor recently bought a new position in Opiant Pharmaceuticals stock. Northern Trust Corp purchased a new position in shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,372 shares of the technology company’s stock, valued at approximately $350,000. Northern Trust Corp owned about 0.86% of Opiant Pharmaceuticals as of its most recent SEC filing. 4.51% of the stock is currently owned by hedge funds and other institutional investors.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.